- Home
- VYGR vs OPP Comparison
VYGR vs OPP Comparison
Compare VYGR & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VYGR | OPP |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.4M | 204.0M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | VYGR | OPP |
|---|---|---|
| Price | $4.15 | $7.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 468.2K | 108.0K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,316,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $71.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.65 | $7.26 |
| 52 Week High | $6.47 | $8.83 |
Technical Indicators
Market Signals| Indicator | VYGR | OPP |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 37.04 |
| Support Level | $4.24 | $7.94 |
| Resistance Level | $4.58 | $8.03 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 48.52 | 25.00 |
Price Performance
Historical ComparisonAbout VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.